RSV

Respiratory Syncytial Virus

The CANVAS surveillance network aims to find out how often health problems occur after an RSV vaccine or monoclonal antibody treatments. This could provide information on frequency and severity of adverse events from RSV vaccines or monoclonal antibody treatments.

Location: British Columbia, Alberta, Ontario, Quebec, Nova Scotia, PEI, and Yukon Territory.

Read More
canvas-network-homepage3-small-1.png

Study Summary

The Canadian National Vaccine Safety (CANVAS) network’s RSV Study is new for 2024 and is interested in the following participants:

  1. People 60+ years old, who were vaccinated with Arexvy or ABRYSVO in the last 7 days
  1. Pregnant people vaccinated with ABRYSVO in the last 7 days
  1. Parents/guardians of babies and children up to 2 years old given nirsevimab, (also known as Beyfortis), a monoclonal antibody immunization

The CANVAS RSV study is currently active in British Columbia, Alberta, Ontario, Quebec, Nova Scotia, and Yukon Territory. After collecting and analyzing the data, we will post the study results on this site. Please check back later.

Scroll to Top